Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended
	May 01, 2023	Feb. 29, 2020	Mar. 31, 2024	Dec. 31, 2023	Aug. 31, 2022
Class of Stock [Line Items]
Term of orphan drug exclusivity	7 years
Ordinary shares, nominal value (in dollars per share)			$ 0.01	$ 0.01
Preferred shares, shares issued (in shares)			0	5,194,000
Preferred shares, shares outstanding (in shares)			0	5,194,000
Preferred shares
Class of Stock [Line Items]
Shares converted (in shares)			(5,194,000)
Ordinary shares
Class of Stock [Line Items]
Shares converted (in shares)			5,194,000
2020 Shelf Registration Statement
Class of Stock [Line Items]
Sales agent commission, as a percent of aggregate gross sales proceeds		3.00%
Maximum aggregate offering price of ADSs under shelf registration		$ 50,000
2022 Shelf Registration Statement
Class of Stock [Line Items]
Maximum aggregate offering price of ADSs under shelf registration					$ 100,000
At-The-Market Offering Program
Class of Stock [Line Items]
Aggregate net proceeds from stock offering			$ 9,250
Remaining authorized aggregate offering price under shelf registration			$ 86,528
At-The-Market Offering Program | American Depositary Shares
Class of Stock [Line Items]
Shares sold in offering (in shares)			640,000